Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 8:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 649 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eczema, Atopic Clear all
Completed No phase listed Observational Accepts healthy volunteers

Sebum Collection and Skin Barrier Function Analysis

NCT03112876
View directory record Official record
Conditions
Smoking, Acne, Atopic Dermatitis, Aging
Interventions
Skin Surface Lipid Collection and Skin Barrier Function
Other
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 9, 2026, 8:58 PM EDT
Recruiting Phase 3 Interventional

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

NCT06807268
View directory record Official record
Conditions
Eczema
Interventions
Abrocitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 9, 2026, 8:58 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT03738423
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
REGN3500, REGN3500-Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 9, 2026, 8:58 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification

NCT00124709
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Corticosteroid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
3 Months to 18 Months
Enrollment
1,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 9, 2026, 8:58 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

NCT04086121
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 9, 2026, 8:58 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT03736967
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
REGN3500, Dupilumab, REGN3500 + Dupilumab Combo, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 9, 2026, 8:58 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
82
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 9, 2026, 8:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluating the Effects of Cleansers on the Skin

NCT03188653
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CeraVe® Eczema Soothing Body Wash, Cetaphil® RestoraDerm® Eczema Calming Body Wash, Dove® Sensitive Skin Body Wash, Eucerin® Skin Calming Body Wash, Aveeno® Skin Relief Body Wash, MooGoo® Milk Wash, Free & Clear Liquid Cleanser
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 9, 2026, 8:58 PM EDT
Completed Phase 2 Interventional

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

NCT04693195
View directory record Official record
Conditions
Chronic Pruritus, Atopic Dermatitis
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
28
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 9, 2026, 8:58 PM EDT
Completed No phase listed Observational

Scratching Validation Study

NCT05137093
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Actigraphy Device
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Maplewood, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 9, 2026, 8:58 PM EDT
Recruiting Phase 4 Interventional

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

NCT05042258
View directory record Official record
Conditions
Atopic Dermatitis, Sleep Disturbance
Interventions
Dupilumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 9, 2026, 8:58 PM EDT
Completed Not applicable Interventional

Bleach Bath Treatment of Adults With Atopic Dermatitis

NCT01996150
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
bleach bath (sodium hypochlorite)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 9, 2026, 8:58 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal

NCT05688735
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Isosorbide Diester Moisturizer, Control Moisturizer
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 9, 2026, 8:58 PM EDT
Completed Phase 4 Interventional Results available

Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis

NCT01093469
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Atopiclair Nonsteroidal Cream, Aquaphor Healing Ointment, EpiCeram
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 9, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis

NCT01806662
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ustekinumab, Placebo
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 9, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

NCT03822832
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
BI 655130, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 9, 2026, 8:58 PM EDT
Recruiting No phase listed Observational

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

NCT06899204
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 9, 2026, 8:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

NCT05277571
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
UCB1381, Placebo
Biological · Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
16
States / cities
Beverly Hills, California • Glendale, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 9, 2026, 8:58 PM EDT
Terminated Phase 4 Interventional Results available

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

NCT03539601
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%, Crisaborole Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Bryant, Arkansas • Encinitas, California • Orange Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 9, 2026, 8:58 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

NCT02118792
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2%, Matching vehicle control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Henrico, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 9, 2026, 8:58 PM EDT
Terminated Phase 2 Interventional

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

NCT05935085
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
ANB032, Placebo
Drug
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
41
States / cities
Anaheim, California • Cerritos, California • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 9, 2026, 8:58 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

NCT01568489
View directory record Official record
Conditions
Mild to Moderate Atopic Dermatitis
Interventions
HL-009 Liposomal Gel, Placebo
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Arlington Heights, Illinois • Fridley, Minnesota • Berlin, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 9, 2026, 8:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

ADRN Barrier/Immunoprofiling Exploratory Pilot Study

NCT02115399
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Non-atopic Healthy Controls
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Denver, Colorado • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 9, 2026, 8:58 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis

NCT00806221
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
emollient (Cetaphil cream)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Up to 1 Month
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 9, 2026, 8:58 PM EDT